Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Table 4

Comparing the toxicities for patients who were <75 years or ≥75 years old.

CTCAE terminology	Belotecan (188 cycles)				value	Topotecan (65 cycles)				value
	<75 years; (124 cycles)		≥75 years; (64 cycles)			<75 years; (53 cycles)		≥75 years; (12 cycles)
	Number	%	Number	%		Number	%	Number	%
Hematological toxicity
Anemia	82	66.1	42	65.6	0.945	35	66	7	58.3	0.741
Neutropenia	72	58.1	49	76.6	0.012	38	71.7	9	75	1.000
Thrombocytopenia	55	44.4	23	35.9	0.267	33	62.3	7	58.3	1.000
Nonhematological toxicity
Generalized muscle weakness	11	8.9	11	17.2	0.093	10	18.9	0	0
Anorexia	15	12.1	9	14.1	0.702	9	17	0	0
Constipation	2	1.6	5	7.8	0.046	4	7.5	2	16.7	0.305
Nausea	12	9.7	3	4.7	0.232	5	9.4	0	0
Vomiting	4	3.2	1	1.6	0.663	2	3.8	0	0
Dyspnea	1	0.8	3	4.7	0.115	3	5.7	0	0
Lung infection	8	6.5	3	4.7	0.752	7	13.2	2	16.7	0.667
Dizziness	5	4.0	1	1.6	0.666	5	9.4	0	0
Myalgia	2	1.6	2	3.1	0.606	0	0	0	0
Sinus tachycardia	0	0	0	0		1	1.9	0	0
Headache	6	4.8	0	0		7	13.2	0	0
Cough	1	0.8	0	0		0	0	0	0
Diarrhea	3	2.4	5	7.8	0.124	3	5.7	3	25	0.071
Skin rash	1	0.8	4	6.3	0.047	2	3.8	0	0
Intracranial hemorrhage	1	0.8	0	0		0	0	0	0
TB increased	0	0	0	0		1	1.9	0	0
AST/ALT increased	2	1.6	1	1.6	1.000	3	5.7	0	0
Abdominal pain	3	2.4	0	0		1	1.9	0	0
Hiccups	6	4.8	1	1.6	0.426	1	1.9	0	0
Fever	5	4.0	2	3.1	1.000	1	1.9	0	0
Confusion	0	0	0	0		1	1.9	0	0
Hyponatremia	3	2.4	0	0		2	3.8	0	0
Delirium	0	0	0	0		1	1.9	0	0
Insomnia	2	1.6	0	0		0	0	0	0
Tremor	1	0.8	0	0		0	0	0	0
Sore throat	2	1.6	1	1.6	1.000	0	0	0	0
URI	0	0	1	1.6		0	0	0	0
Viral hepatitis	0	0	1	1.6		0	0	0	0
Dyspepsia	0	0	0	0		1	1.9	0	0
Ileus	0	0	0	0		1	1.9	0	0
Atrial fibrillation	1	0.8	0	0		0	0	0	0
Hypokalemia	1	0.8	0	0		0	0	0	0
Pleural infection	1	0.8	0	0		1	1.9	0	0

CTCAE: Common Terminology Criteria for Adverse Events, TB: total bilirubin, ALT: alanine transaminase, AST: aspartate transaminase, and URI: upper respiratory tract infection.